Építés alatt – nem éles oldal
Belépés

What researchers published on Mielodiszplasztikus szindróma (MDS)

8390 papers, newest first.

Showing 60 of 8390

  • EsetismertetésPrimary Cutaneous Cryptococcosis Presenting as Flexor Tendon Sheath Infection in a Patient With Myelodysplastic Syndrome: A Case Report.Cureus
  • Clinical and molecular characteristics associated with megakaryocytic dysplasia in patients with myelodysplastic syndromes.Hematology (Amsterdam, Netherlands)
  • ÁttekintésNovel and emerging agents for myelodysplastic syndromes/neoplasms.Expert opinion on investigational drugs
  • Oral Versus Intravenous Hypomethylating Agents in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multicenter Real-World Toxicity Comparison.Acta haematologica
  • New diagnostic criteria can inflate myelodysplastic syndrome survival estimates.Journal of the National Cancer Institute
  • SRSF2 mutations contribute to bone marrow immune microenvironment alterations.Cell death & disease
  • An Unusual Presentation of Erythropoietin-Induced Acute Monoarthritis in a Patient With Myelodysplastic Syndrome and Behçet Disease: A Case Report.The Journal of rheumatology
  • Fever of Unknown Origin in Myelodysplastic Syndrome: Clinical and Laboratory Features of a Chinese Cohort.Journal of clinical medicine
  • AI-assisted single-cell transcriptomics defines immunosuppressive ecosystem states and CD274-centered communication networks in myelodysplastic syndrome.Frontiers in cell and developmental biology
  • Optimizing Reduced-Intensity Conditioning for Older Patients with AML and MDS: A Large-Scale Analysis from the CIBMTR.Blood
  • Aligning Clinical Trial Reporting: A systematic analysis and position statement by the International Consortium for MDS.Blood
  • Teclistamab in multiple myeloma with coexisting myelodysplastic syndrome or acute myeloid leukemia.Haematologica
  • Exploring neuropsychological alterations in VEXAS syndrome.Clinical and experimental medicine
  • EsetismertetésMyelodysplastic Syndrome With Isolated del(5q) Coexisting With Cold Agglutinin Disease Presenting as Unexplained Hyperbilirubinemia.Cureus
  • Development and validation of a baseline interpretable prognostic model for mortality risk stratification in myelodysplastic syndrome patients receiving hypomethylating agent therapy.Current problems in cancer
  • MicroRNA dysregulation in mesenchymal stromal cells in myelodysplastic syndromes and its modulation by azacitidine and bortezomib.Leukemia & lymphoma
  • ÁttekintésSGLT2 Inhibitors and Hemoglobin Improvement in Myelodysplastic Syndromes and Myeloproliferative Neoplasms: Mechanistic Rationale and Emerging Clinical Evidence.Anemia
  • Mesenchymal stromal cells drive immune escape in MDS and sAML through metabolic rewiring of NK cells.Leukemia
  • Integrating functional marrow reserve and molecular risk improves prediction of post-transplant outcomes in HMA-treated myelodysplastic syndromes.Blood neoplasia
  • PreprintPersistent Malignant Stem Cells Drive Relapse After Transplantation in the Myelodysplastic Neoplasms.bioRxiv : the preprint server for biology
  • Luspatercept in Myelodysplastic Syndromes With Ring Sideroblasts: Long Term Outcome and Impact on Non-Erythroid Blood Counts.Hematological oncology
  • Impact of Venetoclax Bridging on Haematopoietic Stem Cell Transplantation Outcomes in Advanced Myelodysplastic Neoplasms.Transplantation and cellular therapy
  • NUDT21 knockdown modulates alternative polyadenylation and promotes leukemic transformation in myelodysplastic syndromes.Neoplasma
  • Molecular and clinical profiling of SF3B1, U2AF1, and SRSF2 mutations in Iranian patients with myelodysplastic neoplasms.Molecular biology reports
  • Frontline isocitrate dehydrogenase inhibitor therapy in isocitrate dehydrogenase-mutated myelodysplastic neoplasms.Haematologica
  • Prevalence and prognostic implications of systemic autoinflammatory and autoimmune diseases in myelodysplastic neoplasms: a retrospective Belgian cohort study.Clinical and experimental medicine
  • GATA2 Deficiency Presenting With a WHIM-Like Phenotype and Subsequent Development of Monosomy 7-Associated Myelodysplastic Syndrome in an Adolescent Female: A Case Report.Clinical case reports
  • Áttekintés[Hematological features and advancement in the diagnosis of VEXAS syndrome].Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • Willingness to Pay for Temporary Transfusion Independence in Lower-Risk Myelodysplastic Syndromes: Evidence from a Cross-Sectional Study in China.Patient preference and adherence
  • Complement deposition in the bone marrow of patients with myelodysplastic neoplasms.Signal transduction and targeted therapy
  • Can we better evaluate responses in higher-risk myelodysplastic syndromes?Haematologica
  • Infectious burden and cellular immune impairment in higher-risk myelodysplastic syndromes with biallelic TP53 alterations.Frontiers in cellular and infection microbiology
  • Áttekintés[Advances in the management of myelodysplastic neoplasms].[Rinsho ketsueki] The Japanese journal of clinical hematology
  • EsetismertetésPearls & Oy-sters: Beyond the Bone Marrow-VEXAS Syndrome Presenting as Subacute Encephalomyelitis.Neurology
  • A Novel Insight Into Luspatercept: Therapeutic Implications in Myelodysplastic Syndrome Patients With Elevated Pulmonary Artery Systolic Pressure.Pulmonary circulation
  • IDH2 p.R172 mutation Predicts Superior Outcomes in IDH-mutated Acute Myeloid Leukemia or Myelodysplastic Syndrome patients undergoing Allogeneic Hematopoietic Cell Transplantation: a retrospective study from the Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH-TC).Transplantation and cellular therapy
  • Comparison of Fludarabine/Treosulfan Conditioning with Melphalan-Based Sequential Conditioning in Patients with MDS and Increased Blasts Undergoing Upfront Transplantation.Cancers
  • ÁttekintésDiagnostic and Clinical Considerations in Myeloid Neoplasms with del(5q): Distinguishing Myelodysplastic Neoplasm with Low Blasts and del(5q) from Myeloid Neoplasms with del(5q) Post-Cytotoxic Therapy.Genes
  • Correction: Balaian et al. Systemic Metabolic Changes in Plasma of Patients with Myelodysplastic Neoplasms and Chronic Myelomonocytic Leukemia. Metabolites 2026, 16, 648.Metabolites
  • Inflammasome activation promotes the progression of myelodysplastic syndrome.Experimental hematology
  • Post-transplant monitoring of NGS-based measurable residual disease and donor chimerism as a prognostic tool in older patients with AML/MDS.Blood research
  • ÁttekintésClinical applications of CD34+ progenitor cell immunophenotyping in myelodysplastic neoplasms-The CytHem SMD French network experience.Cytometry. Part B, Clinical cytometry
  • PreprintMulti-hit STAG2 mutations define a high-risk subset of MDS and reveal convergent evolutionary targeting of cohesin.bioRxiv : the preprint server for biology
  • From ribosomal stress to clonal adaptation: Del(5q) MDS as a paradigmatic acquired ribosomopathy.Seminars in hematology
  • Patient-derived neomorphic SEPTIN6 mutations induce hematopoietic stem cell senescence underlying congenital neutropenia and myelodysplasia.JCI insight
  • A novel CD123xVδ2 bispecific T cell engager induces potent and tumor selective Vγ9Vδ2-T cell activity against CD123 expressing acute myeloid leukemia and myelodysplastic syndrome.Clinical immunology (Orlando, Fla.)
  • A comparison of overall survival and quality of life in patients with MDS treated with azacytidine vs decitabine.Blood neoplasia
  • Venetoclax plus hypomethylating agent improves response rates but not survival in TP53-mutated myelodysplastic syndromes.Blood neoplasia
  • EsetismertetésA rare case of acute basophilic leukemia transformed from high risk myelodysplastic syndrome.Annals of hematology
  • ÁttekintésPersonalized allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes: Integrating molecular risk, donor selection, and post-transplant strategies.Cell transplantation
  • Venetoclax-based combinations in high-risk myelodysplastic syndromes: highlights from ASH 2025 & EHA 2026.Experimental hematology & oncology
  • Áttekintés[Recommendations of the Groupe Francophone des Myélodysplasies (GFM) - Diagnostic approach and management of myelodysplastic syndromes, chronic myelomonocytic leukemias, and VEXAS syndrome].Bulletin du cancer
  • Association between chronic kidney disease and the risk of myelodysplastic syndromes: A large claims database study in Japan.British journal of haematology
  • Financial burden to patients and informal carers of myelodysplastic syndromes in England: a modelled analysis stratified by transfusion dependence.Leukemia research
  • Synchronous myelodysplastic syndrome and multiple myeloma: a DDX41-associated double-hit across two lineages.Archives of medical science : AMS
  • Perspectives on FDA Guidance for Myelodysplastic Syndromes.Blood advances
  • A Stem Cell-based Flow Cytometry Assay to Predict Post-transplantation Relapse in Patients With Myelodysplastic Syndromes With Excess Blasts: A Prospective Study.Transplantation and cellular therapy
  • ÁttekintésOncostatin M deficiency: A newly recognized inherited bone marrow failure syndrome with potential predisposition to myeloid malignancy.Hematology/oncology and stem cell therapy
  • Germline DDX41 defines a distinct subgroup in MDS undergoing transplantation with reduced relapse and improved survival.Blood
  • EsetismertetésAortic-renal aneurysm in a patient with VEXAS syndrome treated with Tocilizumab.ARP rheumatology